ALGS Q3 2021 Earnings — Aligos Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ALGSAligos Therapeutics, Inc.

$45M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M

Gross Profit

$2M100.0% margin

Operating Income

-$33M-2151.5% margin

Net Income

-$33M-2155.1% margin

EPS (Diluted)

$-0.78

QoQ Revenue Growth

-0.5%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$25M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$263M

Total Liabilities

$46M

Stockholders' Equity

$217M

Cash & Equivalents

$240M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$0	—
Gross Profit	$2M	$0	—
Operating Income	-$33M	-$22M	-53.4%
Net Income	-$33M	-$33M	+0.5%